How Do Elderly Poor Prognosis Patients Tolerate Palliative Concurrent Chemoradiotherapy for Locally Advanced Non–Small-Cell Lung Cancer Stage III? A Subset Analysis From a Clinical Phase III Trial

Strøm, Hans Henrik; Bremnes, Roy M.; Sundstrøm, Stein; Helbekkmo, Nina; Aasebø, Ulf

doi:10.1016/j.cllc.2014.08.005

Cited by 19 publications

(7 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…12 In another subset analysis, the advantages of CC appeared preserved for the elderly. 13 Both of these recent studies have limitations. Perhaps the largest is the undefined nature of this patient population.…”

Section: Narrativementioning

confidence: 99%

Palliative thoracic radiation therapy for non-small cell lung cancer: 2018 Update of an American Society for Radiation Oncology (ASTRO) Evidence-Based Guideline

Moeller

Balagamwala

Chen

et al. 2018

Practical Radiation Oncology

View full text Add to dashboard Cite

show abstract

Section: Narrativementioning

confidence: 99%

Palliative thoracic radiation therapy for non-small cell lung cancer: 2018 Update of an American Society for Radiation Oncology (ASTRO) Evidence-Based Guideline

Moeller

Balagamwala

Chen

et al. 2018

Practical Radiation Oncology

View full text Add to dashboard Cite

show abstract

“…For patients in early stage (I/II), surgery provides the best chance for cure (Brunelli, Kim, Berger, & Addrizzo‐Harris, ; Handforth et al, ). For inoperable LSqCC patients (stage III/IV), the prognosis remains poor (Strom, Bremnes, Sundstrom, Helbekkmo, & Aasebo, ). To evaluate the predictive values of lincRNA candidates in LSqCC staging, logistic regression was performed and ORs were calculated in 497 PT samples with definite tumor stage.…”

Section: Resultsmentioning

confidence: 99%

Transcriptional profiling of long‐intergenic noncoding RNAs in lung squamous cell carcinoma and its value in diagnosis and prognosis

Liu

Yao

et al. 2019

Molec Gen & Gen Med

View full text Add to dashboard Cite

BackgroundLong intergenic noncoding RNAs (lincRNAs) are a series of novel transcribed regions expressed in cancers that may represent candidate biomarkers for lung squamous cell carcinoma (LSqCC) treatment. In this study, we evaluated the lincRNA profile in LSqCC patients and screened valuable lincRNAs for diagnosis and prognosis.MethodsTranscriptome profiling of 549 samples derived from 501 LSqCC patients were identified in TCGA database. 48 patients had paired primary tumor (PT) and solid normal (SN) tissue samples, while 453 patients had only PT samples. 1,771 lincRNA candidates were evaluated. Paired test (Wilcoxon two‐sample paired signed rank tests) was performed in paired PT and SN samples. Logistic regression analysis were performed in independent 453 PT samples and 48 SN samples to screen the significant lincRNAs candidates for malignances. Independent 501 PT samples were further used to screen the significant lincRNAs candidates for prognosis.ResultsAmong 1,771 lincRNAs, 10 lincRNAs were significant highly‐expressed risk candidates in PT samples, and 10 protective lincRNAs candidates were significant lowly‐expressed in PT samples. Among 10 highly‐expressed risk lincRNAs, a small panel of LINC00487, LINC01927, and C10orf143 (LINC00959) could effectively predict malignancies in paired samples (AUC = 0.7274, 95%CI = (0.6264, 0.8285)). When combined with protective lincRNA candidates LINC02315, LINC00491, and LINC01697, the predictive efficiency was greatly improved in both paired samples (AUC = 0.8030, 95%CI = (0.7250, 0.8810)) and independent samples (AUC = 0.7481, 95%CI= (0.6642, 0.8320)). Additionally, three highly‐expressed risk lincRNAs, LINC01031, LINC01088, and LINC01931, were significantly associated with poor prognosis in PT samples, suggesting potential targets for anti‐LSqCC treatment.ConclusionTherefore, lincRNAs could be promising biomarkers for predicting malignancies and potential anti‐LSqCC targets for drug development.

show abstract

“…The elderly was defined as patients aged ≥70 years in accordance with common practice. 5 , 8 , 18 , 21 , 22 Age was a stratification factor specified in the original protocol. The aims of this analysis were to 1) explore the characteristics, treatment, prognosis, and safety of therapy in elderly patients (aged ≥70 years) with advanced NSCLC; 2) compare the results with those of younger patients.…”

Section: Methodsmentioning

confidence: 99%

“… 6 , 7 Some trials suggested that elderly patients have a poor prognosis and unresectable tumor. 8 Other studies have showed that lung cancer in young patients may constitute an entity with distinct clinicopathologic characteristics. 9 , 10 Thus, it is still controversial whether younger patients have better or worse outcomes compared with the older counterparts with lung cancer.…”

Section: Introductionmentioning

confidence: 99%

Analysis of the characteristics and prognosis of advanced non-small-cell lung cancer in older patients

Gao¹,

Gao²,

Ma³

et al. 2015

PPA

View full text Add to dashboard Cite

ObjectiveLung cancer is still the leading cause of cancer-related deaths worldwide. However, most elderly patients with advanced non-small-cell lung cancer (NSCLC) have been undertreated and the outcome related to age is controversial. A retrospective analysis was conducted for advanced NSCLC in order to investigate the characteristics and prognosis of older patients.MethodsMedical records were collected from 165 patients with NSCLC (stages IIIA–IIIB) who had been treated with concurrent chemoradiotherapy (CRT) or radiotherapy from January 2009 to January 2011. The cases were divided into two age groups 1) patients ≥70 years old; 2) patients <70 years old. There were 73 patients in group I, 92 in group II. Patient characteristics, treatment toxicities, and prognosis were evaluated.ResultsOf the 165 patients analyzed, 34 patients (34/73) in group I received concurrent CRT while 47 (47/92) in group II completed that treatment. No significant difference was observed in the reason for patients who discontinued CRT in two groups (P>0.05). In the patients with adenocarcinoma, more cases were found in group II than that in group I; the more squamous cell carcinoma and the more smokers with squamous cell carcinoma were seen in older group (P<0.05). With a median follow-up of 20.5 months, the 1-year survival for group I and II were 49.3% and 40.2% respectively (P=0.243). Two-year survival for the two groups was 20.5% and 16.3% (P=0.483); 3-year survival was 9.6% and 9.8% (P=0.967). There was no significant difference between two groups statistically in survival by univariate analysis (P>0.05). The therapy-related toxicities in group I seem to be similar to the group II (P>0.05).ConclusionMore adenocarcinoma patients were found in youthful lung cancer and the more smokers with squamous cell carcinoma were seen in older group. Age is not the important factor for the selection and allocation of treatment in advanced NSCLC. The same prognosis and toxicities had been shown in older and young. Age may not be an independent increased risk of death in advanced NSCLC.

show abstract

How Do Elderly Poor Prognosis Patients Tolerate Palliative Concurrent Chemoradiotherapy for Locally Advanced Non–Small-Cell Lung Cancer Stage III? A Subset Analysis From a Clinical Phase III Trial

Cited by 19 publications

References 39 publications

Palliative thoracic radiation therapy for non-small cell lung cancer: 2018 Update of an American Society for Radiation Oncology (ASTRO) Evidence-Based Guideline

Palliative thoracic radiation therapy for non-small cell lung cancer: 2018 Update of an American Society for Radiation Oncology (ASTRO) Evidence-Based Guideline

Transcriptional profiling of long‐intergenic noncoding RNAs in lung squamous cell carcinoma and its value in diagnosis and prognosis

Analysis of the characteristics and prognosis of advanced non-small-cell lung cancer in older patients

Contact Info

Product

Resources

About